MARKET

CRVS

CRVS

Corvus Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.530
-0.010
-0.28%
Closed 16:00 12/13 EST
OPEN
3.660
PREV CLOSE
3.540
HIGH
3.820
LOW
3.490
VOLUME
245.00K
TURNOVER
--
52 WEEK HIGH
8.10
52 WEEK LOW
2.530
MARKET CAP
103.02M
P/E (TTM)
-2.2440
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of CRVS and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

CRVS News

  • Corvus Pharmaceuticals Presents Preclinical and Initial Clinical Data from the Phase 1/1b Trial of CPI-818 at ASH 2019
  • Benzinga.12/07 18:48
  • Corvus Pharmaceuticals Presents Preclinical and Initial Clinical Data from the Phase 1/1b Trial of CPI-818 at the American Society of Hematology (ASH) Annual Meeting
  • GlobeNewswire.12/07 14:00
  • The Daily Biotech Pulse: Therapix Calls Off Merger, Alimera's Reverse Split, 2 Biotechs To Debut
  • Benzinga.11/08 13:16
  • Corvus Pharmaceuticals Presents Updated Data from CPI-006 Phase 1/1b Clinical Trial at 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting
  • GlobeNewswire.11/08 12:00

More

Industry

Biotechnology & Medical Research
+1.07%
Pharmaceuticals & Medical Research
-0.32%

Hot Stocks

Name
Price
%Change

About CRVS

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response. The Company's lead product candidate, CPI-444, is an oral, small molecule antagonist of the A2A receptor for adenosine, an immune checkpoint. Its other products include adenosine production inhibitor (a monoclonal anti-CD73 antibody); adenosine A2B antagonist, and interleukin-2 (IL-2)-inducible T cell kinase (ITK) inhibitors. As of September 30, 2016, the Company had not generated any revenue.
More

Webull offers Corvus Pharmaceuticals Inc (CRVS) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.